No Prescription |
 |
 | ||
|
ANTIFLU Tamiflu |
|
| ||
No Prescription » Prescription Drugs 1 » ANTIFLU Tamiflu Oseltamivir is an antiviral medication that blocks the actions of influenza virus types A and B in your body. Oseltamivir is used to treat flu symptoms caused by influenza virus in patients who have had symptoms for less than 2 days. Antiflu is used for: Preventing the flu. It is also used for treating the flu in patients within 2 days of the onset of flu symptoms. Buy ANTIFLU Tamiflu and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About ANTIFLU Tamiflu: Product Type: Prescription Drugs 1 ANTIFLU ( Tamiflu Generic Oseltamivir ) ANTIFLU (Tamiflu Generic Oseltamivir) Tamiflu Generic Oseltamivir 75mg 10 ( 1 x 10 Tabs ) 75mg 20 ( 2 x 10 Tabs ) 75mg 30 ( 3 x 10 Tabs ) 75mg 40 ( 4 x 10 Tabs ) 75mg 80 ( 8 x 10 Tabs ) Tamiflu Generic Oseltamivir ANTIFLU
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
